Related Experiment Videos
Therapeutic options in nonulcer dyspepsia
1Department of Medicine, Nepean Hospital, Kingswood, Australia. ntalley@med.usyd.edu.au
Journal of Clinical Gastroenterology
|March 29, 2001
Summary
Dyspepsia, or upper abdominal discomfort, affects millions annually. Functional dyspepsia (NUD) pathophysiology is unclear, with treatments varying by subtype, necessitating novel therapeutic approaches.
Area of Science:
- Gastroenterology
- Internal Medicine
- Pharmacology
Background:
- Dyspepsia affects 25% of the U.S. population, causing significant healthcare costs.
- Functional dyspepsia (nonulcer dyspepsia, NUD) is diagnosed when no organic cause is found.
- NUD pathophysiology involves gastrointestinal motility and sensation disturbances.
Purpose of the Study:
- To review the clinical presentation and pathophysiology of NUD.
- To evaluate current and emerging therapeutic strategies for NUD subtypes.
- To highlight the need for new treatments targeting NUD's underlying mechanisms.
Main Methods:
- Literature review of NUD pathophysiology and treatment efficacy.
- Analysis of clinical trial data for agents like cisapride and antidepressants.
- Discussion of emerging prokinetic and neuromodulating agents.
Main Results:
- Ulcer-like NUD responds to antisecretory therapy; dysmotility-like NUD does not.
- Cisapride shows efficacy but has cardiac toxicity concerns.
- Antidepressants are widely used but their efficacy is uncertain.
Conclusions:
- NUD management requires subtype differentiation.
- Existing treatments have limitations, underscoring the need for safer, more effective options.
- Future NUD treatments will likely involve novel prokinetics and enteric neuromodulators.